Real-world Treatment Outcomes of Lanadelumab in the Prevention of Hereditary Angioedema Attacks: an Interim Analysis of a Polish, Prospective, Multicenter, Observational Study (CHOPIN)
CHOPIN is a noninterventional, multicenter study assessing the effectiveness and safety of lanadelumab in Polish patients with hereditary angioedema (HAE) in the National Drug Program (NCT05147181). (Source: Journal of Allergy and Clinical Immunology)
Source: Journal of Allergy and Clinical Immunology - February 1, 2024 Category: Allergy & Immunology Authors: Aleksandra Kucharczyk, Tomasz Matuszewski, Marcin Kurowski, Aldona Juchacz, Maria Tomasial-Lozowska, Ewa Tr ębas-Pietraś, Robert Pawłowicz, Małgorzata Sokołowska, Małgorzata Pawlukiewicz, Magdalena Zakrzewska, Krzysztof Kuziemski, Marta Tykwińska, Source Type: research

Understanding The Reasons Not To Treat All HAE Attacks And Patient Satisfaction For On-Demand Treatment (ODT). Results From The HAE Wave II Disease Specific Program ™ (DSP™) 2023
The notion that HAE patients do not treat all attacks is familiar to experts but the reasons have not been thoroughly documented in literature. (Source: Journal of Allergy and Clinical Immunology)
Source: Journal of Allergy and Clinical Immunology - February 1, 2024 Category: Allergy & Immunology Authors: Joan Mendivil, John Anderson, Laurence Bouillet, Paula Busse, Teresa Caballero, William Lumry, Markus Magerl, Marc Riedl, Patrick Yong, Andrea Zanichelli, Lucy Earl Source Type: research

Biologic Pathways Involved In Adult-Onset AD And Response To Dupilumab Treatment
Previously a cutaneous transcriptomic signature useful for diagnostic and treatment-response for monitoring AD was identified. Adult-onset atopic dermatitis (AOAD) is recognized as a new AD endotype. However, a similar signature has not been identified for AOAD. (Source: Journal of Allergy and Clinical Immunology)
Source: Journal of Allergy and Clinical Immunology - February 1, 2024 Category: Allergy & Immunology Authors: Debajyoti Ghosh, Jonathan Bernstein Source Type: research

Assessment of the Tolerability and Effectiveness of Berotralstat for Long-term Prophylaxis in Hereditary Angioedema: Berolife Study Interim Analysis
Berotralstat is a first-line, once-daily (QD) oral inhibitor of plasma kallikrein for prophylaxis of hereditary angioedema (HAE) attacks in patients ≥12 years old. While awaiting marketing approval in France, berotralstat qualified for an authorization for temporary use (ATU) in a cohort of patients aged ≥12 years with Type 1 or 2 HAE. Berolife is a French post-ATU observational study assessing the safety and effectiveness of berotralstat. (Source: Journal of Allergy and Clinical Immunology)
Source: Journal of Allergy and Clinical Immunology - February 1, 2024 Category: Allergy & Immunology Authors: Laurence Bouillet, Delphine Gobert, Isabelle Boccon-gibod, David Launay, Mona Villedieu, Jean-Charles Crave, Douglas Johnston, Olivier Fain Source Type: research

Dupilumab Reduces Disease Activity in Patients with Chronic Spontaneous Urticaria: LIBERTY-CSU CUPID Study A
Chronic spontaneous urticaria (CSU) is a chronic inflammatory disease characterized by wheals and/or angioedema that recur for>6 weeks. The overall goal of CSU treatment is to clear the signs and symptoms until urticaria shows spontaneous remission. Many patients with CSU fail to respond adequately to standard-of-care H1-antihistamines (H1-AH). (Source: Journal of Allergy and Clinical Immunology)
Source: Journal of Allergy and Clinical Immunology - February 1, 2024 Category: Allergy & Immunology Authors: Marcus Maurer, Ana Gimenez-Arnau, Allen Kaplan, Sarbjit Saini, Luis Felipe Ensina, Michihiro Hide, Amy Praestgaard, Tayler Gonzalez, Sonya Cyr, Philip Sugerman Source Type: research

Phase 2 Open-Label Extension Study With Donidalorsen in Patients With Hereditary Angioedema: 1 Year Versus 2 Years
The phase 2 open-label extension (OLE) study of donidalorsen in patients with Type 1/2 hereditary angioedema (HAE) (NCT04307381) revealed a 95% mean reduction in attacks and improved quality of life (QoL) with donidalorsen at Year 1. A comparison of Years 1 and 2 results is presented. (Source: Journal of Allergy and Clinical Immunology)
Source: Journal of Allergy and Clinical Immunology - February 1, 2024 Category: Allergy & Immunology Authors: Raffi Tachdjian, Laura Bordone, Steve Dorow, Danny Cohn, Eugene Schneider, Yiwen Deng, Kenneth Newman, Veronica Alexander, Marc Riedl Source Type: research

Efficacy And Safety Of Bradykinin B2 Receptor Antagonism With Oral Deucrictibant In Prophylaxis Of Hereditary Angioedema Attacks: Results Of CHAPTER-1 Phase 2 Trial
In hereditary angioedema (HAE), swelling attacks are caused by excessive bradykinin activating the bradykinin B2 receptors. Deucrictibant (PHA121) is a potent, selective, orally administered antagonist of bradykinin B2 receptor under development for on-demand and prophylactic treatment of HAE attacks. (Source: Journal of Allergy and Clinical Immunology)
Source: Journal of Allergy and Clinical Immunology - February 1, 2024 Category: Allergy & Immunology Authors: Marc Riedl, John Anderson, Francesco Arcoleo, Mauro Cancian, Hugo Chapdelaine, Niall Conlon, Efrem Eren, Mark Gompels, Sofia Grigoriadou, Maria Guarino, Padmalal Gurugama, Tamar Kinaciyan, Markus Magerl, Michael Manning, Marcin Stobiecki, Michael Tarzi, A Source Type: research

Updated Results of a Phase 1a Trial of STAR-0215 for Hereditary Angioedema
STAR-0215 is an investigational extended half-life monoclonal antibody for hereditary angioedema (HAE). This trial (NCT05477160) assesses STAR-0215's potential for safe and durable suppression of HAE attacks after single doses in healthy subjects. (Source: Journal of Allergy and Clinical Immunology)
Source: Journal of Allergy and Clinical Immunology - February 1, 2024 Category: Allergy & Immunology Authors: William Lumry, Christopher Morabito, Theodora Cohen, Michele Gunsior, Kristine Bernard, Pamela Gustafson Source Type: research

Pediatric Doses Of neffy (Intranasal Nasal Spray) Demonstrate Pharmacokinetic Profiles That Are Equivalent To Epinephrine Injections Products
Epinephrine is the first-line treatment for severe allergic reactions, including anaphylaxis. Despite epinephrine ’s well documented history of safety and efficacy, patients/caregivers frequently fail to treat or delay treating severe allergic reactions, citing challenges of carrying epinephrine auto-injectors and concerns about injection. These concerns are particularly pronounced in pediatric patients, who, along with their caregivers, tend to be more anxious about injectable devices. An intranasal epinephrine spray (neffy) is being developed as a needle-free option for the treatment of severe allergic reactions. (Sour...
Source: Journal of Allergy and Clinical Immunology - February 1, 2024 Category: Allergy & Immunology Authors: David Fleischer, H. Henry Li, Richard Lockey, Michael Kaliner, Wayne Shreffler, Richard Lowenthal, Sarina Tanimoto Source Type: research

Pharmacokinetics and Pharmacodynamics of Epinephrine Following Administration via Sublingual Film, Autoinjector, or Manual Injection
AQST-109, a sublingual film containing a novel prodrug of epinephrine (DESF), is under development for the emergency treatment of Type 1 allergic reactions. The final formulation of AQST-109 was compared with epinephrine delivered by two different approved autoinjectors (EpiPen and Auvi-Q) or by manual injection (IM). (Source: Journal of Allergy and Clinical Immunology)
Source: Journal of Allergy and Clinical Immunology - February 1, 2024 Category: Allergy & Immunology Authors: David Golden, Jay Lieberman, David Bernstein, John Oppenheimer, Mark Freedman, Carl Kraus, Stephen Wargacki Source Type: research

Pharmacodynamic Profile of Epinephrine Nasal Spray Versus Intramuscular Epinephrine Autoinjector in Healthy Adults
Standard of care for anaphylaxis treatment is intramuscular (IM) epinephrine. An epinephrine nasal spray (ENS) is under development as an alternative form of administration. This analysis compared the pharmacodynamic (PD) profile of 13.2 mg ENS with 0.3 mg IM epinephrine autoinjector. (Source: Journal of Allergy and Clinical Immunology)
Source: Journal of Allergy and Clinical Immunology - February 1, 2024 Category: Allergy & Immunology Authors: Jay Lieberman, David Bernstein, Michael Blaiss, Lawrence Dubuske, David Fleischer, Matthew Greenhawt, John Oppenheimer, David Dworaczyk Source Type: research

Pharmacokinetic Profile of Epinephrine Nasal Spray Versus Intramuscular Epinephrine Autoinjector in Healthy Adults
An epinephrine nasal spray (ENS) is under development for treatment of anaphylaxis. This analysis compared the pharmacokinetic (PK) profile of 13.2 mg ENS with that of the standard of care 0.3 mg intramuscular (IM) epinephrine autoinjector. (Source: Journal of Allergy and Clinical Immunology)
Source: Journal of Allergy and Clinical Immunology - February 1, 2024 Category: Allergy & Immunology Authors: Matthew Greenhawt, David Bernstein, Michael Blaiss, Lawrence Dubuske, David Fleischer, Jay Lieberman, John Oppenheimer, David Dworaczyk Source Type: research

Real world outcome of children treated with dupilumab for severe atopic dermatitis in a single specialist center
This study looked at real-world outcomes of dupilumab in children of different ethnicities attending a specialist center in the UK. (Source: Journal of Allergy and Clinical Immunology)
Source: Journal of Allergy and Clinical Immunology - February 1, 2024 Category: Allergy & Immunology Authors: Timothy Clayton, Michelle Herring, Georgina Devlin, Mozhgan Hosseini-Ashrafi Source Type: research

Dupilumab Consistently Reduces CCL-17 (TARC) in Patients with Atopic Dermatitis Across All Age Groups
Elevated serum C-C motif chemokine ligand 17 (CCL17)/thymus and activation-regulated chemokine (TARC) has been associated with atopic dermatitis (AD) severity. Reductions in type 2 inflammatory biomarkers such as CCL17/TARC have been reported in adult patients with moderate-to-severe AD treated with dupilumab. (Source: Journal of Allergy and Clinical Immunology)
Source: Journal of Allergy and Clinical Immunology - February 1, 2024 Category: Allergy & Immunology Authors: Lisa Beck, Mark Boguniewicz, Yoko Kataoka, Marjolein de Bruin-Weller, Antonella Muraro, Zhen Chen, Ainara Rodriguez-Marco, Parul Shah, Ana Rossi Source Type: research

Probiotic Lactobacillus in the Treatment of Atopic Dermatitis in Premature Children from Kyiv, Ukraine
Atopic dermatitis (AD) in premature infants is a major health issue for which there is limited evidence for the use of probiotics as treatment. The efficacy of the probiotic Lactobacillus (LGG) was assessed in premature infants with AD from the Kyiv, Ukraine region. (Source: Journal of Allergy and Clinical Immunology)
Source: Journal of Allergy and Clinical Immunology - February 1, 2024 Category: Allergy & Immunology Authors: Olena Sharikadze, Viktor Litus, Olexander Litus, Iryna Litus, Lawrence Dubuske Source Type: research